Covaxin Is Safe, Enhanced Immune Response in Phase 1 Trial: Lancet India’s first indigenous COVID vaccine candidate, led to ‘tolerable safety outcomes’ and ‘enhanced immune responses’ in the phase 1 trial, revealed an interim report published in The Lancet #Covaxin#COVID#Vaccine Read the full article: fit.thequint.com/coronavirus/vaccine-treatment/cov…
Quint Fit
Covaxin Is Safe, Enhanced Immune Response in Phase 1 Trial: Lancet
India’s first indigenous COVID vaccine candidate, led to ‘tolerable safety outcomes’ and ‘enhanced immune responses’ in the phase 1 trial, revealed an interim report published in The Lancet
#Covaxin #COVID #Vaccine
Read the full article: fit.thequint.com/coronavirus/vaccine-treatment/cov…
4 years ago | [YT] | 6